About
Liv Svenningsson Krogstad serves as a Doctoral Research Fellow at the University of Oslo's Section for Pharmacology and Pharmaceutical Biosciences, conducting research at the intersection of pharmacology, neuroscience, and genetics. Her work investigates molecular mechanisms of brain disorders through genetic and biochemical approaches, with institutional affiliation centered on neuropharmacological research.
Her primary research spans pharmacology, pharmaceutical biosciences, neuroscience, and genetics, specializing in neurogenetics and molecular pharmacology. She focuses on protein modifications (particularly N-terminal acetylation) and their role in neurodegenerative conditions like primary familial brain calcifications, aiming to elucidate pathogenic mechanisms for therapeutic development. This integrates molecular biology, genetic analysis, and pharmacological modeling to address neurological disease pathways.
Her 2024 Nature Communications publication on NAA60 variants demonstrates her contribution to genetic brain disorder research, highlighting a trend toward molecular precision in neuropharmacology. This work links specific genetic mutations to disease phenotypes, advancing targeted intervention strategies for calcification disorders through mechanistic insights into protein function.
She actively participates in the LIPIDBRAIN research group and Neurobiology & Toxicology team, collaborating on lipid-related brain pathologies and neurotoxicological mechanisms. These affiliations drive interdisciplinary projects examining molecular underpinnings of neurological conditions through pharmacological and genetic lenses.
Research fields
